Importantly, these findings highlight the central role of BCL-2 family proteins in promoting ATLL cell survival and therapy resistance, and they establish BCL-2 inhibition as a promising therapeutic strategy. This evidence concerns the gene BCL2 and adult T-cell leukemia/lymphoma.